Published in Vaccine on March 21, 2010
Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits. Trials Vaccinol (2014) 0.76
Synthetic DNA delivery systems. Nat Biotechnol (2000) 4.82
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med (1989) 2.74
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol (1997) 2.04
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine (1995) 1.79
Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine (2007) 1.76
CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol (1995) 1.72
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol (1989) 1.27
Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol (2001) 1.24
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16
Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J Virol (2002) 1.15
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine (2001) 1.15
Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection. J Virol Methods (2007) 1.11
Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol (2002) 1.10
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09
Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies. Antivir Chem Chemother (2005) 1.09
In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. J Immunol Methods (1992) 1.08
Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine (2000) 1.08
Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol (1999) 1.06
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol (2010) 1.06
Improving vaccine delivery using novel adjuvant systems. Hum Vaccin (2008) 1.05
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood (2004) 1.05
Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology (1998) 1.05
Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology (2002) 1.04
Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res (2009) 1.02
DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol (2000) 1.02
Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine (1999) 1.01
Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol (2000) 0.98
Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine (1998) 0.97
Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol (2004) 0.95
Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J Immunol (2003) 0.94
CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology (2004) 0.94
Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Immunol (1993) 0.93
The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci (2008) 0.92
Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model. Viral Immunol (2006) 0.92
Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells. J Exp Med (1988) 0.91
Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol (2002) 0.89
The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett (2004) 0.88
A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D (2008) 0.88
An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol (1999) 0.88
Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. Cancer Res (2001) 0.88
Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv (2006) 0.87
Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model. J Virol (2007) 0.86
Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother (2005) 0.86
Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit model. Vaccine (2007) 0.83
Oral vaccine delivery--new strategies and technologies. Curr Drug Deliv (2009) 0.82
Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob Agents Chemother (2001) 0.81
GM-CSF enhances protective immunity to cottontail rabbit papillomavirus E8 genetic vaccination in rabbits. Vaccine (2004) 0.77
Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol (2002) 1.66
Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection. J Virol Methods (2007) 1.11
Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo. Virology (2006) 1.10
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98
Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit model. Vaccine (2007) 0.83
Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model. J Gen Virol (2015) 0.77
Characterization of a 0.35T MR system for phantom image quality stability and in vivo assessment of motion quantification. J Appl Clin Med Phys (2015) 0.77